Matthew H. Taylor, MD, Oregon Health and Science University, discusses the efficacy and safety of lenvatinib for the treatment of patients with 131I-refractory differentiated thyroid cancer with and without prior VEGF-targeted therapy.
Matthew H. Taylor, MD, Oregon Health and Science University, discusses the efficacy and safety of lenvatinib for the treatment of patients with131I
Molecular Targets Making Headway in Pediatric Thyroid Cancer Research
March 16th 2023In an interview with Targeted Oncology, Aime T. Franco, PhD, discussed the molecular landscape of pediatric patients with thyroid cancer and the presentation she gave at the 91st Annual Meeting of the American Thyroid Association.
Read More
Real-World Data Supports Avelumab Use for Locally Advanced, Metastatic Urothelial Carcinoma
February 20th 2023Treatment with avelumab for locally advanced or metastatic urothelial carcinoma showed to be consistent in a real-world with what was previously seen in the phase 3 JAVELIN Bladder 100 trial.
Read More
2 Clarke Drive
Cranbury, NJ 08512